Abstract

Benefits and limitations in using NCCN guidelines to distinguish TP53 CH from mosaic LFS.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
National Comprehensive Cancer Network Guidelines: Who Makes Them? What Are They? Why Are They Important?
Lenora A Pluchino ... Thomas A D’Amico
The Annals of thoracic surgery | VOL. 110
Lenora A Pluchino, et. al.Lenora A Pluchino ... Thomas A D’Amico
13 Apr 2020
Cancer risk assessment models versus National Comprehensive Cancer Network guidelines: What is the most comprehensive method to assess cancer risk and triage for genetic testing? (373)
Isabel Wolfe ... Melissa Frey
Gynecologic oncology | VOL. 166
Isabel Wolfe, et. al.Isabel Wolfe ... Melissa Frey
01 Aug 2022
Precision Adjuvant Therapy Based on Detailed Pathologic Risk Factors for Resected Oral Cavity Squamous Cell Carcinoma: Long-Term Outcome Comparison of CGMH and NCCN Guidelines
...
International Journal of Radiation Oncology, Biology, Physics | VOL. 106
, et. al. ...
06 Sep 2019
Analysis of decision making at a multidisciplinary head and neck tumor board incorporating evidence-based National Cancer Comprehensive Network (NCCN) guidelines
Bhartesh A Shah ... Minh Tam Truong
Practical Radiation Oncology | VOL. 6
Bhartesh A Shah, et. al.Bhartesh A Shah ... Minh Tam Truong
14 Nov 2015
View more papers

More From: JCO Precision Oncology

Paper Title
Journal
Date
Author
TAPping Into PD-L1 Testing Efficiency for Gastroesophageal Cancer.
Brian S Henick ... Ryan H Moy
JCO Precision Oncology | VOL. 8
Brian S Henick, et. al.Brian S Henick ... Ryan H Moy
01 Jul 2024
Clinical Response to Olaparib in a Patient With Leptomeningeal Carcinomatosis in Newly Diagnosed Breast Cancer With Germline BRCA2 Mutation.
Manali Shah ... Alice J Cohen
JCO Precision Oncology | VOL. 8
Manali Shah, et. al.Manali Shah ... Alice J Cohen
01 Jul 2024
Deciphering Disease Profiles in the Era of Prostate-Specific Membrane Antigen Positron Emission Tomography: Aggressive or Indolent?
Peter D Zang ... Wesley Yip
JCO Precision Oncology | VOL. 8
Peter D Zang, et. al.Peter D Zang ... Wesley Yip
01 Jul 2024
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.
Scott Schuetze ... Richard L Schilsky
JCO Precision Oncology | VOL. 8
Scott Schuetze, et. al.Scott Schuetze ... Richard L Schilsky
01 Jul 2024
View more papers